Investigating a protein's role in triple-negative breast cancer
Pentraxin-3 in the Pathogenesis and Management of Triple-Negative Breast Cancer
['FUNDING_R01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-10880443
This study is looking at a protein called PTX3 to see if it can help doctors understand and treat triple-negative breast cancer better, by checking its levels in patients and seeing if lowering it can help fight the cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10880443 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a protein called Pentraxin-3 (PTX3) in triple-negative breast cancer (TNBC), a type of breast cancer that is often resistant to standard treatments. The study aims to identify PTX3 as a potential biomarker for TNBC, which could help in assessing patient risk and guiding treatment decisions. Researchers will analyze PTX3 levels in patient samples and explore how it influences cancer cell behavior, including growth and resistance to chemotherapy. By neutralizing PTX3, the study seeks to determine if it can lead to cancer cell death, offering a new therapeutic approach for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who may benefit from new treatment strategies.
Not a fit: Patients with other types of breast cancer or those who are not diagnosed with breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and targeted therapies for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promising results in targeting similar biomarkers in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KARNOUB, ANTOINE ELIAS — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: KARNOUB, ANTOINE ELIAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.